Atriomx Health, a Menlo Park, California-based developer of novel, non-invasive solutions for the detection and characterization of the underlying disease mechanisms of atrial fibrillation and other arrhythmias, secured a $10m Series A financing.
The round was co-led by Ajax Health and Zeus Health.
The company intends to use the funds for initial development and clinical study of its hardware, software, and algorithmic solutions.
In conjunction with the Series A financing, Atriomx Health has appointed Mike Carter to serve as the company’s Chief Operating Officer.
